Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)1053-1054
Number of pages2
JournalBJU International
Volume112
Issue number8
DOIs
StatePublished - Dec 2013

Fingerprint

Local Neoplasm Recurrences
Antineoplastic Antibiotics
Aminolevulinic Acid
Cystoscopy
Photosensitizing Agents
Photochemotherapy
Mitomycin
Urinary Bladder Neoplasms
Fluorescence
Drug Therapy
5-aminolevulinic acid hexyl ester

ASJC Scopus subject areas

  • Urology

Cite this

@article{81fe6fa55d9744e8b5a0b644c52db7a6,
title = "Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?",
author = "Yair Lotan",
year = "2013",
month = "12",
doi = "10.1111/bju.12411",
language = "English (US)",
volume = "112",
pages = "1053--1054",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?

AU - Lotan, Yair

PY - 2013/12

Y1 - 2013/12

UR - http://www.scopus.com/inward/record.url?scp=84887311044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887311044&partnerID=8YFLogxK

U2 - 10.1111/bju.12411

DO - 10.1111/bju.12411

M3 - Article

VL - 112

SP - 1053

EP - 1054

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 8

ER -